Scope
Reference
C371747
Description
Vaccine mimic materials-comprising messenger RNA (mRNA) and lipid nanoparticles (LNPs)-from Helix-Biotech.
Contract 1. Helix Biotech Biosimilar mRNA Vaccines
Supplier
Contract value
- £150,000 excluding VAT
- £180,000 including VAT
Above the relevant threshold
Earliest date the contract will be signed
1 September 2025
Contract dates (estimated)
- 8 September 2025 to 7 September 2027
- 2 years
Main procurement category
Goods
CPV classifications
- 33651600 - Vaccines
Participation
Particular suitability
- Small and medium-sized enterprises (SME)
- Voluntary, community and social enterprises (VCSE)
Other information
Description of risks to contract performance
A valid and current Cyber Essentials Certificate is required.
Conflicts assessment prepared/revised
Yes
Procedure
Procedure type
Direct award
Direct award justification
Single supplier - technical reasons
Helix-Biotech Inc. is the only supplier capable of delivering the required vaccine mimic materials (mRNA encapsulated in LNPs) with validated equivalence to licensed Pfizer-style COVID-19 vaccines. Their proprietary methodology and formulation capability are not available from other suppliers, nor covered under any current public procurement frameworks.
Supplier
Helix Biotech, Inc.
- Public Procurement Organisation Number: PCMD-6995-GBGZ
1460 Breda Drive
Knoxville
37918
United States
Email: info@helix-biotech.com
Small or medium-sized enterprise (SME): Yes
Voluntary, community or social enterprise (VCSE): No
Contract 1. Helix Biotech Biosimilar mRNA Vaccines
Contracting authority
UK Health Security Agency
- Public Procurement Organisation Number: PBMQ-7576-DVGW
10 South Colonnade
London
E14 4PU
United Kingdom
Email: commercial.preparednessandcountermeasures@ukhsa.gov.uk
Website: https://www.gov.uk/government/organisations/uk-health-security-agency
Region: UKI42 - Tower Hamlets
Organisation type: Public authority - central government